DIOBEX BEGINS TYPE 2 DIABETES DRUG TRIAL

DiObex has begun treating patients with Type 2 diabetes in a randomized, placebo-controlled Phase II trial. Patients will be treated for two weeks to evaluate the safety and pharmacokinetics of three dose levels of the cortisol synthesis inhibitor DIO-902.

DIO-902 (2S,4R ketoconazole) is one of the two enantiomers contained within the racemate of the drug ketoconazole. A racemate is a mixture of equal quantities of two enantiomers, substances whose molecular structures are mirror images of one another. DIO-902 has been proven to be both more effective and safer than the racemate in preclinical studies.